Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Initial data from the phase I/II ELEVATE-44-201 trial demonstrated favorable safety and early functional improvements in ambulatory patients with Duchenne muscular dystrophy.
Entrada Therapeutics (NASDAQ:TRDA) has reported initial data from the first cohort of its phase I/II ELEVATE-44-201 clinical trial. The trial is focused on treating ambulatory patients suffering from Duchenne muscular dystrophy, commonly referred to as DMD. Specifically, the study targets patients who possess genetic mutations that are amenable to exon 44 skipping.[1][2]
According to the company, the preliminary results from this first cohort indicated a clean safety profile, demonstrating favorable safety and tolerability among the participants. Alongside the safety data, the trial also revealed early signs of functional improvement in the ambulatory patients receiving the treatment.[1][2]
The clinical trial results were formally reviewed by the company during a conference call. The presentation of the phase I/II ELEVATE-44-201 data was led by the Chief Executive of Entrada Therapeutics, highlighting the early functional gains and safety metrics observed in the study.[1]
